| The treatment of ovarian cancer has evolved from a traditional approach based on pathological type, grading, and staging to a biomarker-driven paradigm emphasizing precise, personalized, and targeted therapies. While ovarian cancer demonstrates substantial genetic heterogeneity, current clinical practice reveals both underutilization and inappropriate overuse of genetic testing. Notably, standardized protocols for evidence-based genetic testing tailored to clinical needs at different treatment phases remain undefined in domestic and international guidelines. This consensus document, developed by an expert panel through systematic evaluation of evidence, comprehensive review of global literature, and integration of current guidelines and clinical expertise, aims to establish practical recommendations for the rational application of genetic testing in ovarian cancer management across therapeutic decision points. |
